11C-Methionine uptake in meningiomas after stereotactic radiotherapy

IF 2.5 4区医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Annals of Nuclear Medicine Pub Date : 2024-05-08 DOI:10.1007/s12149-024-01932-6

Hanne-Rinck Jeltema, Bart R. J. van Dijken, Katalin Tamási, Gea Drost, Mart A. A. M. Heesters, Anouk van der Hoorn, Andor W. J. M. Glaudemans, J. Marc C. van Dijk

{"title":"11C-Methionine uptake in meningiomas after stereotactic radiotherapy","authors":"Hanne-Rinck Jeltema, Bart R. J. van Dijken, Katalin Tamási, Gea Drost, Mart A. A. M. Heesters, Anouk van der Hoorn, Andor W. J. M. Glaudemans, J. Marc C. van Dijk","doi":"10.1007/s12149-024-01932-6","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p><sup>11</sup>C-Methionine positron emission tomography (MET-PET) is used for stereotactic radiotherapy planning in meningioma patients. The role of MET-PET during subsequent follow-up (FU) is unclear. We analyzed the uptake of <sup>11</sup>C-Methionine before and after stereotactic radiotherapy (SRT) in patients with a complex meningioma and investigated if there was a difference between patients with progressive disease (PD) and stable disease (SD) during FU.</p><h3>Methods</h3><p>This retrospective study investigates 62 MET-PETs in 29 complex meningioma patients. Standardized uptake value (SUV)<sub>max</sub> and SUV<sub>peak</sub> tumor-to-normal ratios (T/N-ratios) were calculated, comparing the tumor region with both the mirroring intracranial area and the right frontal gray matter. The difference in <sup>11</sup>C-Methionine uptake pre- and post-SRT was analyzed, as well as the change in uptake between PD or SD.</p><h3>Results</h3><p>Median (IQR) FU duration was 67 months (50.5–91.0). The uptake of <sup>11</sup>C-Methionine in meningiomas remained increased after SRT. Neither a statistically significant difference between MET-PETs before and after SRT was encountered, nor a significant difference in one of the four T/N-ratios between patients with SD versus PD with median (IQR) SUV<sub>max</sub> T/N<sub>R front</sub> 2.65 (2.13–3.68) vs 2.97 (1.55–3.54) [<i>p</i> = 0.66]; SUV<sub>max</sub> T/N<sub>mirror</sub> 2.92 (2.19–3.71) vs 2.95 (1.74–3.60) [<i>p</i> = 0.61]; SUV<sub>peak</sub> T/N<sub>R front</sub> 2.35 (1.64–3.40) vs 2.25 (1.44–3.74) [<i>p</i> = 0.80]; SUV<sub>peak</sub> T/N<sub>mirror</sub> 2.38 (1.91–3.36) vs 2.35 (1.56–3.72) [<i>p</i> = 0.95].</p><h3>Conclusions</h3><p>Our data do not support use of MET-PET during FU of complex intracranial meningiomas after SRT. MET-PET could not differentiate between progressive or stable disease.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"38 8","pages":"596 - 606"},"PeriodicalIF":2.5000,"publicationDate":"2024-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11282149/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Nuclear Medicine","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s12149-024-01932-6","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

¹¹C-Methionine positron emission tomography (MET-PET) is used for stereotactic radiotherapy planning in meningioma patients. The role of MET-PET during subsequent follow-up (FU) is unclear. We analyzed the uptake of ¹¹C-Methionine before and after stereotactic radiotherapy (SRT) in patients with a complex meningioma and investigated if there was a difference between patients with progressive disease (PD) and stable disease (SD) during FU.

Methods

This retrospective study investigates 62 MET-PETs in 29 complex meningioma patients. Standardized uptake value (SUV)_max and SUV_peak tumor-to-normal ratios (T/N-ratios) were calculated, comparing the tumor region with both the mirroring intracranial area and the right frontal gray matter. The difference in ¹¹C-Methionine uptake pre- and post-SRT was analyzed, as well as the change in uptake between PD or SD.

Results

Median (IQR) FU duration was 67 months (50.5–91.0). The uptake of ¹¹C-Methionine in meningiomas remained increased after SRT. Neither a statistically significant difference between MET-PETs before and after SRT was encountered, nor a significant difference in one of the four T/N-ratios between patients with SD versus PD with median (IQR) SUV_max T/N_{R front} 2.65 (2.13–3.68) vs 2.97 (1.55–3.54) [p = 0.66]; SUV_max T/N_mirror 2.92 (2.19–3.71) vs 2.95 (1.74–3.60) [p = 0.61]; SUV_peak T/N_{R front} 2.35 (1.64–3.40) vs 2.25 (1.44–3.74) [p = 0.80]; SUV_peak T/N_mirror 2.38 (1.91–3.36) vs 2.35 (1.56–3.72) [p = 0.95].

Conclusions

Our data do not support use of MET-PET during FU of complex intracranial meningiomas after SRT. MET-PET could not differentiate between progressive or stable disease.

Abstract Image

查看原文本刊更多论文

立体定向放射治疗后脑膜瘤的 11C 蛋氨酸摄取量。

目的：11C-蛋氨酸正电子发射断层扫描（MET-PET）用于脑膜瘤患者的立体定向放射治疗计划。MET-PET 在后续随访（FU）中的作用尚不明确。我们分析了复杂脑膜瘤患者在立体定向放射治疗（SRT）前后对11C-蛋氨酸的摄取情况，并研究了在随访期间疾病进展期（PD）和疾病稳定期（SD）患者之间是否存在差异：这项回顾性研究调查了29名复杂脑膜瘤患者的62例MET-PET。通过比较肿瘤区域与颅内镜像区域和右侧额叶灰质，计算了标准化摄取值（SUV）max和SUVpeak肿瘤与正常比率（T/N-ratios）。分析了SRT前后11C-蛋氨酸摄取量的差异，以及PD或SD之间摄取量的变化：中位（IQR）FU持续时间为67个月（50.5-91.0）。脑膜瘤的 11C 蛋氨酸摄取量在 SRT 后仍有增加。SRT前后的MET-PET之间既没有统计学意义上的显著差异，SD与PD患者之间的四种T/N比值也没有显著差异，中位数（IQR）SUVmax T/NR前值为2.65（2.13-3.68），后值为2.97（1.55-3.54）。97（1.55-3.54）[p = 0.66]；SUVmax T/Nmirror 2.92（2.19-3.71）vs 2.95（1.74-3.60）[p = 0.61]；SUVpeak T/NR front 2.35（1.64-3.40) vs 2.25 (1.44-3.74) [p = 0.80]；SUVpeak T/Nmirror 2.38 (1.91-3.36) vs 2.35 (1.56-3.72) [p=0.95].结论：我们的数据不支持在SRT后的复杂颅内脑膜瘤FU期间使用MET-PET。MET-PET无法区分疾病是进展期还是稳定期。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Annals of Nuclear Medicine 医学-核医学

CiteScore

4.90

自引率

7.70%

发文量

111

审稿时长

4-8 weeks

期刊介绍： Annals of Nuclear Medicine is an official journal of the Japanese Society of Nuclear Medicine. It develops the appropriate application of radioactive substances and stable nuclides in the field of medicine. The journal promotes the exchange of ideas and information and research in nuclear medicine and includes the medical application of radionuclides and related subjects. It presents original articles, short communications, reviews and letters to the editor.